Last updated: April 24, 2024
Sponsor: Stanford University
Overall Status: Active - Recruiting
Phase
2
Condition
Anxiety Disorders
Obsessive-compulsive Disorder
Panic Disorders
Treatment
Fluoxetine
Dextromethorphan
Clinical Study ID
NCT04899687
60569
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD),illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
- Living within California
- Capacity to provide informed consent
Exclusion
Exclusion Criteria:
- Current bipolar disorder or psychotic disorder
- Active moderate or severe substance use disorder, lifetime severe substance usedisorder
- Pregnant or nursing women
- Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior tostudy start
- Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapywithin 2 months of study start
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Fluoxetine
Phase: 2
Study Start date:
January 20, 2022
Estimated Completion Date:
December 01, 2025
Study Description
Connect with a study center
Stanford University
Stanford, California 94304
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.